We have located links that may give you full text access.
Multiplexed LC/ESI-MRM-MS-based Assay for Identification of Coronary Artery Disease Biomarkers in Human Plasma.
Proteomics. Clinical Applications 2019 January 12
PURPOSE: A highly-multiplexed LC/ESI-MRM-MS based assay was developed for the identification of coronary artery disease (CAD) biomarkers in human plasma.
EXPERIMENTAL DESIGN: The assay was used to measure 107 stable isotope labeled peptide standards and native peptides from 64 putative biomarkers of cardiovascular diseases in tryptic digests of plasma from subjects with (n = 70) and without (n = 45) angiographic evidence of CAD and no subsequent cardiovascular mortality during follow-up.
RESULTS: Extensive computational and statistical analysis revealed 6 plasma proteins associated with CAD, namely apolipoprotein CII, C reactive protein, CD5 antigen-like, fibronectin, inter alpha trypsin inhibitor heavy chain H1, and protein S. The identified proteins were combined into a LASSO-logistic score with high classification performance (cross-validated AUC = 0.74). When combined with a separate score computed from markers currently used in the clinic with similar performance, the AUC increased to 0.84. Similar results were observed in an independent set of subjects (n = 87).
CONCLUSIONS AND CLINICAL RELEVANCE: If externally validated, the assay and identified biomarkers can improve CAD risk stratification. This article is protected by copyright. All rights reserved.
EXPERIMENTAL DESIGN: The assay was used to measure 107 stable isotope labeled peptide standards and native peptides from 64 putative biomarkers of cardiovascular diseases in tryptic digests of plasma from subjects with (n = 70) and without (n = 45) angiographic evidence of CAD and no subsequent cardiovascular mortality during follow-up.
RESULTS: Extensive computational and statistical analysis revealed 6 plasma proteins associated with CAD, namely apolipoprotein CII, C reactive protein, CD5 antigen-like, fibronectin, inter alpha trypsin inhibitor heavy chain H1, and protein S. The identified proteins were combined into a LASSO-logistic score with high classification performance (cross-validated AUC = 0.74). When combined with a separate score computed from markers currently used in the clinic with similar performance, the AUC increased to 0.84. Similar results were observed in an independent set of subjects (n = 87).
CONCLUSIONS AND CLINICAL RELEVANCE: If externally validated, the assay and identified biomarkers can improve CAD risk stratification. This article is protected by copyright. All rights reserved.
Full text links
Related Resources
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app